Martin H. Bluth, M.D., Ph.D.
Dr. Bluth also serves as director of Translational Research for the Department of Pathology, and associate director of the Transfusion Service for the Detroit Medical Center.
His areas of research include immunology/inflammation, pancreatology, biomarker discovery, glycolipid based anti-inflammatory therapy, role of IgE in viral diseases and cancer, and blood derived stem cell propogation.
In his role as director of Translation Research, Dr. Bluth is immersed in bringing research from bench to patient bedside, training residents and fellows in applied science, and “synergizing strengths of clinical and basic science toward human application.”
Dr. Bluth said he gravitated toward his research interests because of “the relationship of how basic science research addresses the clinical questions and how the clinical need translates and applies basic science to the human condition.”
He completed his undergraduate studies at Yeshiva University, where he majored in biology. He received his medical and doctorate degrees from Downstate Medical Center in New York. His doctorate degree is in immunology. Dr. Bluth, who is editor in chief of the Journal of Pharmacogenomics and Personalized Medicine (Dove Medical Press) - http://www.dovepress.com/articles.php?journal_id=38 - completed his residency in Clinical Pathology and Laboratory Medicine, as well as a fellowship in Blood Banking and Transfusion Medicine, in which he is dual board certified.
He holds more than 15 new inventions and technologies, many of which are patent pending. Dr. Bluth is also vice president of BioMedica Management Corp., and on the board of directors of FirstPoint Biotech venture fund. He has recently pioneered biomarker discovery platforms for use toward clinical applications and entrepreneurial start-up companies.